Citable filing context
SOLV's research view summarizes recent SEC filing context, starting with restructuring from Aug 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 5, 2026 | restructuring | Solventum announced its intention to separate its Health Information Systems business as part of a portfolio optimization strategy. |
| Aug 5, 2026 | earnings | Solventum reported second-quarter 2026 sales of $2.2 billion and increased its full-year 2026 financial guidance. |
| Jul 20, 2026 | management_change | Solventum appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. |
| Aug 5, 2026 | Guidance: adjusted_eps | 7.10 to 7.20 |
| Aug 5, 2026 | Guidance: free_cash_flow | 200.00 to 300.00 |
| Aug 5, 2026 | Guidance: organic_sales_growth | 2.50 to 3.00 |
| Aug 5, 2026 | mda_quarterly | Solventum Corporation reported a 2.2% increase in second-quarter 2026 net sales to $2.2 billion, bolstered by $125 million in advanced customer orders ahead of a U.S. enterprise resource planning (ERP) deployment. This one-time surge is expected to negatively impact third-quarter sales as inventory levels normalize. Organic growth was strong across all segments, particularly in Dental Solutions (15.2%) and MedSurg (8.9%). However, total company operating income declined 15.8% to $181 million, largely due to increased corporate costs related to the ongoing separation from 3M and legal accruals. Management announced plans to pursue a separation of the Health Information Systems business to optimize the portfolio and enhance shareholder value. Financially, the company benefited from a $120 million IEEPA tariff refund recognized in the second quarter. Liquidity remains supported by cash on hand and access to a $2 billion commercial paper program, though cash from operations decreased year-over-year due to higher incentive compensation and transition-related payments. The company continues to execute a $1 billion share repurchase program, having bought back 3.9 million shares during the quarter. Key risks include ongoing inflationary pressures, tariff volatility, and the operational complexities of establishing a standalone corporate infrastructure. |
| May 5, 2026 | mda_quarterly | Solventum reported first-quarter 2026 net sales of $2.01 billion, a 3.0% reported decline but 2.1% organic growth. Total operating income fell 46.7% to $81 million, pressured by higher SG&A costs related to the 3M separation and the "Transform for the Future" restructuring program. The company recently completed the $4 billion sale of its Purification and Filtration business, while retaining its Water Business. MedSurg sales grew 6.6%, driven by Tegaderm CHG and negative pressure wound therapy, though operating income declined 21.8% due to tariffs and inflation. Dental Solutions saw a 7.9% sales increase led by restorative and prevention solutions, and Health Information Systems grew 4.1% through adoption of Solventum 360 Encompass and Performance Management Solutions. Liquidity tightened, with cash and equivalents falling to $561 million and operating cash flow turning negative at $189 million, primarily due to incentive compensation and 3M transition exit payments. A significant headwind remains the volatile tariff environment; while a Supreme Court ruling regarding the International Emergency Economic Powers Act may lead to future refunds, the company anticipates new tariffs in 2026. Additionally, the company spent $67 million on share repurchases during the quarter. |
Source: SEC EDGAR filing text and events; period Aug 5, 2026; filed Aug 5, 2026.
SOLV company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.